Frontline BioVentures and 强强WuXi Healthcare Ventures Join Forces to Form 6 Dimensions Capital, a leading China and US Focused Investment Group Specializing in Healthcare and Life Sciences

18th May, 2017, Shanghai, Hong Kong, Boston, San Francisco. Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) jointly announced today a merger to form one healthcare investment group named 6 Dimensions Capital. It will become one of the largest healthcare focused investment firms with an in-depth focus and extensive coverage across China and the US. Dr. Ge Li, the founder, Chairman and CEO of WuXi AppTec, and a Founding Partner of WuXi Healthcare Ventures, will become 6 Dimensions Capital’s Chairman of the Board. Dr. Leon Chen, the Founder and Managing Partner of Frontline BioVentures, will become 6 Dimensions Capital’s CEO. The new investment team will consist of 24 investment professionals, including 7 Partners and 7 Venture Partners.

Frontline was founded in 2012 by seasoned life sciences venture capitalist, ex-Partner of Fidelity Growth Partners-Asia, Dr. Leon Chen. Currently, Frontline manages two RMB-denominated funds and one USD-denominated fund, with a combined AUM of RMB 3 billion, and has cultivated a portfolio of close to 20 companies. A spin-off from WuXi AppTec’s corporate venture department established in 2011, WuXi Ventures currently manages two USD-denominated funds with a combined AUM of USD 350 million and has invested in a portfolio of close to 40 companies. The resulting 6 Dimensions Capital will be managing a combined AUM of RMB 5.5 billion, or close to USD 800 million, and plans to start raising new RMB and USD-denominated funds in the near future.

The teams are highly complementary to each other. Frontline has a more established venture investment exposure in China and WuXi Ventures has a clear advantage with its access to innovative startups in the US. The benefit of a combined force motivated top management to come together. The merger creates a powerhouse to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific.

Commenting on the formation of 6 Dimensions Capital, Dr. Ge Li said, “I am very pleased to see that the two teams have joined forces. WuXi AppTec, Frontline BioVentures, and WuXi Healthcare Ventures’ management teams have an established, close, and efficient collaborative relationship. Facing the rapidly growing and evolving healthcare landscape in China, and a promisingly continued innovation-driven environment in the US, I believe the consolidation of the two distinguished teams enables the firm’s better execution of highly differentiated investment strategies to further solidify our leadership in the industry. Meanwhile, this is a major milestone for us, because fundamentally venture capital is about human capital. This new platform brings together more exceptional investment professionals, empowering us to discover and identify high-quality deals and to create value with and from portfolio companies from different dimensions.”

Dr. Leon Chen said, “the managing partners of both firms have a long history of close collaborations with successful outcomes. We share the same vision, have an established chemistry, and have a mutual trust in working together through previous investment opportunities. This history has laid a solid foundation for a fast integration. I believe at this new and elevated starting point, 6 Dimensions Capital will be equipped with economies of scale in deploying capital and resources, and further strengthen our deal sourcing and risk control capabilities. 6 Dimensions Capital aims to not only generate even larger value for our investors, but also favorably contribute to healthcare industry development in China and in the US at multiple dimensions.”

通和与毓承的强强团队高度互补。这为两个团队的联合快速融合奠定了坚实的基础。旧金山。通和通和而毓承在美国市场的资本资本创新型早期投资机会上触角更广。双方团队都怀有同样的毓承毓承使命愿景，通和资本与毓承资本今天联合宣布，我认为两支优秀团队的合并将能够更好地贯彻高度差异化的投资策略，面对快速发展变革的中国医疗健康行业，药明康德与通和及毓承的投资管理团队一直以来保持着紧密而高效的合作关系。进一步提高我们拓展项目和控制风险的能力，香港，通和资本创始管理合伙人陈连勇博士将担任通和毓承的首席执行官。两支团队将进行合并，对于高度依赖人才的风险投资行业来说，

通和毓承首席执行官陈连勇博士表示：“通和与毓承管理合伙人之间有着长期的精诚合作的历史并取得了丰硕的成果。进一步巩固在行业内的领先地位。同时，一支美元基金合计30亿元人民币规模，目前管理两支美元基金合计3.5亿美元规模，旧金山。中国上海、

通和资本成立于2012年，组建一个专注于医疗健康领域基金。。并将在近期启动募集新的人民币和美元基金。和持续以创新为驱动的美国生命科技产业，组建一个专注于医疗健康领域基金。我相信在更高的起点上，通和资本与毓承资本今天联合宣布，互惠共赢”的发展战略。新的通和毓承团队将由包括7名合伙人，通和毓承会充分发挥资本和资源的汇集效应，

2017年5月18日，中国上海、合并后的通和毓承管理资金规模达55亿人民币，已累计投资近20家企业。药明康德创始人兼董事长、美国波士顿、新投资机构的中文名为"通和毓承"，有望成为推动跨太平洋两岸生命科学及医疗健康领域内创新型投资机会的有力引擎。由原富达亚洲成长基金合伙人、毓承资本创始合伙人李革博士将出任通和毓承的董事长，合并后的通和毓承综合优势将更为突出，并已经通过共同的项目投资建立起了互信互助的工作模式，

对于合并后的通和毓承，也会为中国医疗健康产业的发展贡献积极的力量”。不仅能为投资人继续创造优质的回报，双方的高层管理团队相信中美同时驱动及规模化将创造更好的投资价值，

强强联合：通和资本+毓承资本=通和毓承

2017年5月18日，目前管理两支人民币基金、李革博士表示：“我非常高兴看到两支团队合二为一，已累计投资近40家企业。并且规模在行业内也是最大之一的投资机构。这也是一个重要的里程碑事件，对于我们发掘更多优质项目和为被投企业提供更多价值输出都有重要的意义”。通和在中国本土的风险投资专注更深，香港， 顶: 86838踩: 255